Skip to main content

CORRECTION article

Front. Immunol., 27 June 2024
Sec. Viral Immunology
Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1451571

Corrigendum: Epigenetic immune monitoring for COVID-19 disease course prognosis

This article is a correction to:

  1. Epigenetic immune monitoring for COVID-19 disease course prognosis

    1. Read original article
Bjrn Samans,Björn Samans1,2Marta Rossell ChornetMarta Rosselló Chornet3Araceli Rossell ChornetAraceli Rosselló Chornet1Janine JungJanine Jung1Konstantin SchildknechtKonstantin Schildknecht1Laura LozzaLaura Lozza1Lourdes Alos ZaragozaLourdes Alos Zaragoza3Javier Hernndez LaforetJavier Hernández Laforet3Nina BabelNina Babel4Sven Olek*Sven Olek1*
  • 1Ivana Türbachova Laboratory for Epigenetics, Epiontis, Precision for Medicine GmbH, Berlin, Germany
  • 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
  • 3Department of Anesthesiology and Resuscitation, Consortium General University Hospital of Valencia, Valencia, Spain
  • 4Center for Translational Medicine, Medical Clinic 1, Marien Hospital Herne, University Hospitals of the Ruhr-University of Bochum, Herne, Germany

A Corrigendum on
Epigenetic immune monitoring for COVID-19 disease course prognosis

by Samans B, Rosselló Chornet M, Rosselló Chornet A, Jung J, Schildknecht K, Lozza L, Alos Zaragoza L, Hernández Laforet J, Babel N, Olek S. Front Immunol. doi: 10.3389/fimmu.2023.1107900

In the published article, there was an error regarding the affiliations for Björn Samans. As well as having affiliation 1, they should also have affiliation “Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: COVID-19, SARS-CoV-2, epigenetic qPCR, immune monitoring, lymphopenia, disease prognosis

Citation: Samans B, Rosselló Chornet M, Rosselló Chornet A, Jung J, Schildknecht K, Lozza L, Alos Zaragoza L, Hernández Laforet J, Babel N and Olek S (2024) Corrigendum: Epigenetic immune monitoring for COVID-19 disease course prognosis. Front. Immunol. 15:1451571. doi: 10.3389/fimmu.2024.1451571

Received: 19 June 2024; Accepted: 20 June 2024;
Published: 27 June 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Samans, Rosselló Chornet, Rosselló Chornet, Jung, Schildknecht, Lozza, Alos Zaragoza, Hernández Laforet, Babel and Olek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sven Olek, sven.olek@precisionformedicine.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.